Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma (original) (raw)

Abstract

Recently, circulating miRNAs have been reported as promising biomarkers for various pathologic conditions including cancer. Certain microRNAs (miRNAs) have been shown early diagnostic potential for many types of cancer. The objective of this study was to investigate the potential of certain serum/plasma miRNAs as novel non-invasive biomarkers for early diagnosis of hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). For this reason, the expression levels of 24 miRNA (let-7c, miR-92a-3p, 423-5p, 150-5p, 223-3p, 125b-5p, 342-3p, miR-206, 122-5p, 375, 223-5p, 10a-5p, 23b-5p, 99a-5p, 23a-5p, 10a-3p, 122-3p, 125b-1-3p, 23b-3p, 125b-2-3p, 23a-3p, 92a-1-5p, 92a-2-5p, 99a-3p) were analyzed in plasma of patients with chronic hepatitis B, HBV-positive cirrhosis and HBV-positive HCC and compared with control group samples. Totally 94 plasma samples; 28 control and 66 patient plasma (24 CHB, 22 HBV-positive cirrhosis, 20 HBV-positive HCC) and were included in this study. The expression levels of 24 miRNAs were detected for all control and patient group plasma samples by qRT-PCR using BioMark™ 96.96 Dynamic Array (Fluidigm Corporation) system. The expression levels of miR-125b-5p were detected 2.85 fold, 2.46 fold and 1.89 fold (p = 0.01513, p = 0.0009440, p = 0.0001446) up regulated in CHB, HBV-positive cirrhosis and HBV-positive HCC, respectively when compared versus control group individually by Mann–Whitney U test. The expression levels of miR-223-3p were detected 5.55 fold, 13.88 fold and 12.65 fold (p = 0.01513, p = 0.0009440, p = 0.0001446) down regulated in same comparisons. When all groups were compared versus control group by one-way ANOVA test, the expression levels of miR-223-3p were also found statistically significant (p < 0.05). Although not statistically significant, miR-125b-5p tended to be upregulated. (p = 0.07192). These results significantly imply that miR-125b-5p and miR223-3p could be used as novel non-invasive biomarkers of HBV-positive HCC in very early, even at CHB stage of liver disease.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, version 2.0, IARC cancerbase no. 5. IARC Press, Lyon
    Google Scholar
  2. Sun J, Haiqi LuH, Wang X, Jin H (2013) MicroRNAs in hepatocellular carcinoma: regulation function, and clinical implications. Sci World J 2013:924206. doi:10.1155/2013/924206
    Google Scholar
  3. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C (2006) Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25(27):3823–3833
    Article CAS PubMed Google Scholar
  4. Zhu P, Tan D, Peng Z, Liu F, Song L (2007) Polymorphism analyses of hepatitis B virus X gene in hepatocellular carcinoma patients from southern China. Acta Biochim Biophys Sin (Shanghai) 39(4):265–272
    Article CAS Google Scholar
  5. Ozen C, Yildiz G, Dagcan A, Cevik D, Ors A, Keles U, Topel H, Ozturk M (2013) Genetics and epigenetics of liver cancer. N Biotechnol 30(4):381–384. doi:10.1016/j.nbt.2013.01.007
    Article CAS PubMed Google Scholar
  6. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J (2011) Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29(36):4781–4788
    Article CAS PubMed Google Scholar
  7. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF (2011) Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 6(12):e28486. doi:10.1371/journal.pone.0028486
    Article PubMed Central CAS PubMed Google Scholar
  8. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S (2009) Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49(4):1098–1112
    Article CAS PubMed Google Scholar
  9. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K (2010) Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70(23):9798–9807
    Article CAS PubMed Google Scholar
  10. Gorur A, Balci Fidanci S, Dogruer Unal N, Ayaz L, Akbayir S, Yildirim Yaroglu H, Dirlik M, Serin MS, Tamer L (2012) Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep 40(3):2091–2096. doi:10.1007/s11033-012-2267-7
    Article PubMed Google Scholar
  11. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH (2008) Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 14(2):470–477
    Article CAS PubMed Google Scholar
  12. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D (2013) Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 52(4):297–303
    Article CAS PubMed Google Scholar
  13. Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N (2010) MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 16(3):867–875
    Article CAS PubMed Google Scholar
  14. Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, Chen HY, Wang ZW, Qiu GQ, Peng ZH (2012) Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 6(4):445–457
    Article CAS PubMed Google Scholar
  15. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S, Li Y, Gu J (2008) Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 123(7):1616–1622
    Article CAS PubMed Google Scholar
  16. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25(17):2537–2545
    Article CAS PubMed Google Scholar
  17. Qi J, Wang J, Katayama H, Sen S, Liu SM (2013) Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 60(2):135–142
    Article PubMed Central CAS PubMed Google Scholar
  18. Sun YM, Lin KY, Chen YQ (2013) Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 15(6):6. doi:10.1186/1756-8722-6-6
    Article Google Scholar
  19. Bousquet M, Nguyen D, Chen C, Shields L, Lodish HF (2012) MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA. Haematologica 97:1713–1721
    Article PubMed Central CAS PubMed Google Scholar
  20. Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, Nie Y, Wu K, Liu J, Shi Y, Ding J, Fan D (2012) Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One 7:e40169
    Article PubMed Central CAS PubMed Google Scholar
  21. Xu N, Zhang L, Meisgen F, Harada M, Heilborn J, Homey B, Grander D, Stahle M, Sonkoly E, Pivarcsi A (2012) MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J Biol Chem 287:29899–29908
    Article PubMed Central CAS PubMed Google Scholar
  22. Ge Y, Sun Y, Chen J (2011) IGF-II is regulated by microRNA-125b in skeletal myogenesis. J Cell Biol 192:69–81
    Article PubMed Central CAS PubMed Google Scholar

Download references

Acknowledgments

This study was supported by Grants from the Mersin University Scientific Research Funds, Mersin, Turkey [Project no. BAP-SBE TM (BGG) 2011-5 YL].

Author information

Authors and Affiliations

  1. Department of Medical Microbiology, Faculty of Medicine, Mersin University, Mersin, Turkey
    Burcu Gurer Giray, Gurol Emekdas, Seda Tezcan & Mahmut Ulger
  2. Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Mersin University, Yenisehir, 33169, Mersin, Turkey
    Mehmet Sami Serin
  3. Department of Gastroenterology, Faculty of Medicine, Mersin University, Mersin, Turkey
    Orhan Sezgin & Engin Altintas
  4. Department of Hematology, Faculty of Medicine, Mersin University, Mersin, Turkey
    Eyup Naci Tiftik

Authors

  1. Burcu Gurer Giray
  2. Gurol Emekdas
  3. Seda Tezcan
  4. Mahmut Ulger
  5. Mehmet Sami Serin
  6. Orhan Sezgin
  7. Engin Altintas
  8. Eyup Naci Tiftik

Corresponding author

Correspondence toMehmet Sami Serin.

Rights and permissions

About this article

Cite this article

Giray, B.G., Emekdas, G., Tezcan, S. et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma.Mol Biol Rep 41, 4513–4519 (2014). https://doi.org/10.1007/s11033-014-3322-3

Download citation

Keywords